Accessibility Menu
Sigyn Therapeutics logo

Sigyn Therapeutics(OTC) SIGY

Market Cap$40.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-100%
1 Year-99%
1 Month-29%
$0.03
-16.39%
-0.00Today
Sigyn Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.032026-07-28
Sigyn Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.7%USD 0.022026-07-20
1 month-28.57%USD 0.042026-06-26
3 month-49.08%USD 0.052026-04-29
Year to date-98.54%USD 1.712025-12-31
1 year-99.11%USD 2.802025-07-11
3 year-99.54%USD 5.402023-07-25
5 year-99.92%USD 32.002021-07-29
Since inception-99.97%USD 78.802020-10-20

Sigyn Therapeutics Financials at a Glance

Market Cap

$40.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$3.62M

EPS (TTM)

-$2.10

P/E Ratio

-0.01

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.03

Volume

38,500

Open

$0.03

Previous Close

$0.03

Daily Range

$0.02 - $0.03

52-Week Range

$0.01 - $5.00

Estimated Earnings Date

Aug 18, 2026

SIGY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sigyn Therapeutics

Sigyn Therapeutics develops devices to clean harmful substances from blood. Its main product aims to help patients with severe infections or cancer. The company focuses on solutions for hospitals treating life-threatening conditions.

Gadgets in the Bloodstream: What Sigyn Sells

  • Sigyn Therapy: Blood purification device for removing toxins, pathogens, and inflammatory molecules; targets patients with severe infections or sepsis. (0% of revenue; no sales to date)
  • ImmunePrep Platform: Device to improve cancer antibody treatments by removing interfering substances from blood; aimed at cancer patients. (0% of revenue)
  • ChemoPrep: Device to help chemotherapy work better by clearing tumor-related particles; for cancer therapy support. (0% of revenue)
  • ChemoPure: Device to reduce chemotherapy side effects by removing excess drugs from blood; for patients undergoing cancer treatment. (0% of revenue)

Growth Spurts and Strategic Moves

  • Expanded product pipeline in 2024-2025 to include cancer therapy support devices.
  • Launched Regulation D capital raise in January 2025 to fund operations.
  • Terminated San Diego office lease in May 2025 to cut costs.
  • Extended convertible note maturities with major noteholders in August 2025.

Sigyn’s Secret Sauce: What Sets It Apart

Sigyn’s devices are designed for use with standard hospital equipment, aiming for easier adoption. The company holds multiple pending patents for its blood purification technologies. Its management team has experience with devices that received emergency regulatory approvals.

Five Things You Need to Know

  • No revenue reported for Q2 2025 or any prior period.
  • Operating expenses were $469,513 in Q2 2025, down 22.1% from Q2 2024.
  • Net loss was $1,451,187 in Q2 2025, which is $588,804 greater than the $862,383 net loss in Q2 2024.
  • Cash balance was $459 as of June 30, 2025, with a $5.5 million working capital deficit.

Bottom Line

Sigyn remains a development-stage company focused on blood purification devices for critical care. It faces ongoing financial challenges and has not yet commercialized any products.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

4

CEO

Jim A. Joyce

Website

www.sigyntherapeutics.com

Headquarters

San Diego, CA 92106, US

SIGY Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

57.73%

Return on Capital

N/A

Return on Assets

-7197.69%

Earnings Yield

-100.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$40.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.61M

Volume

38.50K

Avg. Volume

23.72K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.54M

EBITDA

-$1.73M

Operating Cash Flow

-$654.39K

Capital Expenditure

-$3.00

Free Cash Flow

-$654.39K

Cash & ST Invst.

$265.00

Total Debt

$3.18M

Sigyn Therapeutics Performance Analysis

Sigyn Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Sigyn Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Sigyn Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.13-5.1%
20232023-12-31USD -3.7720.2%
20242024-12-31USD -2.51-33.5%
20252025-12-31USD -2.09-16.7%
Sigyn Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-114.3%
Q32025-09-3060.0%
Q42025-12-31-13.9%
Q12026-03-31-2.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$40.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.03K

N/A

Employees

4

N/A

Net Income

-$922.56K

-38.0%

EBITDA

-$299.86K

+44.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$265.00

-97.9%

Total Debt

$3.18M

+26.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$3.18M

+28.5%

Return on Assets

-71.98%

N/A

Return on Invested Capital

21.17%

N/A

Free Cash Flow

-$96.56K

+67.2%

Operating Cash Flow

-$96.56K

+67.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PKTXProtoKinetix, Incorporated
$0.00-98.48%
REPCFRepliCel Life Sciences Inc.
$0.00+0.00%
HAVLFHAVN Life Sciences Inc.
$0.00+0.00%
CLABFCore One Labs Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
SKHYSK Hynix
$126.79-0.03%
NOKNokia
$8.41-0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About SIGY

What is the current price of Sigyn Therapeutics?

Sigyn Therapeutics is trading at $0.03 per share.

What is the 52-week range for Sigyn Therapeutics?

Over the past 52 weeks, Sigyn Therapeutics has traded between $0.01 and $5.00.

How much debt does Sigyn Therapeutics have?

As of the most recent reporting period, Sigyn Therapeutics reported total debt of $3.18M.

How much cash does Sigyn Therapeutics have on hand?

Sigyn Therapeutics reported $265.00 in cash and cash equivalents in its most recent financial results.

What is Sigyn Therapeutics’s dividend yield?

Sigyn Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services